Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
about
Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates.Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope TrimerAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinEntry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral HemagglutininProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Functional contributions of carbohydrate on AIDS virus glycoproteinEfficient on-chip isolation of HIV subtypesGeneration of recombinant vaccinia viruses via green fluorescent protein selectionGeneration of random mutant libraries with multiple primers in a single reactionEnvelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.Endothelial galectin-1 binds to specific glycans on nipah virus fusion protein and inhibits maturation, mobility, and function to block syncytia formation.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesTemporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody responseA spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domainMapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.Antibody evasion by a gammaherpesvirus O-glycan shieldElicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challengeSequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsPrime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing.Polyomavirus BK neutralizing activity in human immunoglobulin preparations.Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesTwo closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.The CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1.Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivityEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
P2860
Q27318042-9F41EBC9-F439-4458-83BC-6EE8172D35EFQ27319450-8F93D037-D53C-41AD-99CA-691B2817F60EQ27657377-B52B74C4-106C-4A0E-A705-9C25DA15DC08Q27680497-5014628D-C34E-457E-855F-66BDB3CC1B63Q28485983-6D7B952B-8167-4337-ADC7-473073DE2EEEQ28743092-33A90663-AD1C-4F27-9BE7-33E23FF98D27Q30375215-BC7D84FB-98C1-4904-AB4A-0872471EB43FQ30379200-22336CA9-5F21-484D-947F-C5B83AA8316DQ30397572-B943E164-19AB-45DC-9ACA-2411556B14F1Q30413840-524B7752-BC11-41B5-A09B-14D224094291Q30857503-913A796F-A5CA-48BA-8636-20E79C0FC393Q33548933-CF7AAF90-8D60-41C2-A42C-B13DE1E1EEDEQ33636347-AB4195C5-9113-4B77-9810-CB69A72EBDB2Q33640112-3392CF5A-6278-45EA-8FA7-CE0551D77B19Q33648910-42D594AA-54D9-4119-9732-BE548A24388FQ33664910-07AED592-D639-444A-8EB6-FB3DF154ECD5Q33728690-2E089946-261E-4B81-BC0E-6A096D6D663FQ33826682-22F73A01-C252-46AB-9331-08CB825F6077Q33910507-793C750C-9C1E-490F-9660-F8AA6545A8D3Q33972838-9EA290A9-4DB9-4FE8-874E-7ADBB36959EBQ33980469-CDFBB83D-A747-4C7A-A00C-2612FA1D90E4Q34082672-68A09007-B2F8-4650-9331-07250C8A528AQ34133551-F713D428-214B-4BE3-8267-4B9F6486ACFFQ34178201-859827CB-B9D3-4B1E-9931-75111F2C4066Q34178259-9511776F-57D8-47EE-BC50-E2A50CC5FDDFQ34397758-FD03F2C3-496B-4867-8125-D5492A2E6DCAQ34485260-B98F5A0F-A600-4FAA-A2E7-975ABA3C9459Q34499013-26126219-E912-4872-8F6E-F65B2F9CF812Q34539819-75A41C2C-C2E9-429D-BE61-74230B892093Q34551010-BABC561B-F212-422F-9230-FC2C51A9508CQ34741807-AD6FF1AE-C899-4E7F-832F-AB9C77CB2041Q34742873-5F18CBBE-BE35-47AB-96C9-35B876F81091Q34786755-9AED695D-1275-49B5-8695-226ED86ACEDDQ34885869-B0B73368-F28A-4D92-AE66-DEDF484515C4Q35034268-14E46B8D-A6C0-4275-8070-0EF4EB237CE3Q35076664-AD4882BA-6A1B-4CEE-A262-CF05771901D4Q35079838-6AA14E3F-1B39-4A2A-AB1F-8CCF3207E9E1Q35192782-14E85BF0-6592-442E-BB32-B4E23DDF95E0Q35195445-6C3E9A40-57C3-42BC-B979-A6548E88B2ADQ35666057-65063342-9F4F-4A53-8012-447E516A50C2
P2860
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Removal of a single N-linked g ...... eutralizing antibody responses
@ast
Removal of a single N-linked g ...... eutralizing antibody responses
@en
type
label
Removal of a single N-linked g ...... eutralizing antibody responses
@ast
Removal of a single N-linked g ...... eutralizing antibody responses
@en
prefLabel
Removal of a single N-linked g ...... eutralizing antibody responses
@ast
Removal of a single N-linked g ...... eutralizing antibody responses
@en
P2093
P2860
P356
P1433
P1476
Removal of a single N-linked g ...... eutralizing antibody responses
@en
P2093
Barbra A Richardson
Bradley Cleveland
Bruce Travis
David Anderson
Igor Klots
Patricia Polacino
Shiu-Lok Hu
P2860
P304
P356
10.1128/JVI.01691-07
P407
P577
2007-10-24T00:00:00Z